leisure time -WSS

leisure time

author：comprehensive 2025-10-01 22:57:25 - browse：767

Cambridge: Biogen — Ruby Wallau for STAT

Biogen is joining the industry’s fervor over immune and inflammatory disease drug development with a new acquisition.

The Cambridge, Mass., drugmaker announced Wednesday that it will acquire Human Immunology Biosciences, or HI-Bio, for $1.15 billion and up to $650 million in additional payments if certain milestones are met.

HI-Bio, which is based in San Francisco, is developing therapies for immune-mediated diseases like primary membranous nephropathy and IgA nephropathy, both of which impact kidney function. The startup’s lead drug, felzartamab, is a monoclonal antibody that selectively depletes CD38+ and natural killer cells in the hopes of alleviating the disease’s effects. It has already completed Phase 2 studies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： George Santos makes 1st court appearance after pleading not guilty to 13 counts
Next article： Do digital therapeutics have a future in medicine?

WSS

Medicare drug price negotiation’s day in court

Reconstructing family trees of blood cells may help predict disease

Philips to halt sales of sleep apnea machines in U.S.

Why Medicare shouldn’t cover every FDA

What we need to know about Arena Bioworks

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Apple is now the first public company to be valued at $3 trillion

Reconstructing family trees of blood cells may help predict disease

Psychedelics group wrestles with new pharma identity

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Jerome Adams on the need for new antivirals for Covid

Medicare drug price negotiation legal challenge met with skepticism

In Memoriam: Notable people who died in 2023

Medicare Advantage insurers face 0.2% cut to 2025 payments

Medicare details structure of new drug price negotiation program

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

focus

Reconstructing family trees of blood cells may help predict disease

Syphilis numbers in the United States reach record heights

Venture capital firm's plans to take over Akron hospital face hurdles

Cybersecurity threat forces Lurie Children's to take systems offline

FTC sues over Novant Health acquisition of two N.C. hospitals

Novo Nordisk to expand supply of Wegovy for U.S. patients

leisure time

explore

Wikipedia

hotspot